Loriot Y - Search Results

1

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Routy B, et al. Among authors: loriot y. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2. Science. 2018. PMID: 29097494

2

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.

Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC. Loriot Y, et al. Nat Clin Pract Oncol. 2008 May;5(5):268-78. doi: 10.1038/ncponc1087. Epub 2008 Mar 18. Nat Clin Pract Oncol. 2008. PMID: 18349858 Review.

3

MVP and vinorelbine for malignant pleural mesothelioma.

Mordant P, Loriot Y, Soria JC, Deutsch E. Mordant P, et al. Among authors: loriot y. Lancet. 2008 Aug 23;372(9639):629; author reply 629-30. doi: 10.1016/S0140-6736(08)61273-8. Lancet. 2008. PMID: 18722865 No abstract available.

4

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Fizazi K. Loriot Y, et al. Ann Oncol. 2009 Apr;20(4):703-8. doi: 10.1093/annonc/mdn694. Epub 2009 Jan 29. Ann Oncol. 2009. PMID: 19179557 Free article.

5

Wound healing delay after central venous access following DCF/VEGF-trap therapy.

Ferté C, Massard C, Moldovan C, Desruennes E, Loriot Y, Soria JC. Ferté C, et al. Among authors: loriot y. Invest New Drugs. 2009 Dec;27(6):583-5. doi: 10.1007/s10637-009-9227-7. Epub 2009 Feb 17. Invest New Drugs. 2009. PMID: 19221694

6

[Molecular aspects of head and neck, and lung cancer oncogenesis].

Loriot Y, Mordant P, Fouret P, Deutsch E, Soria JC. Loriot Y, et al. Bull Cancer. 2009;96 Suppl 1:S13-24. doi: 10.1684/bdc.2009.0786. Bull Cancer. 2009. PMID: 19433370 Review. French.

7

Are RAS mutations predictive markers of resistance to standard chemotherapy?

Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Loriot Y, et al. Nat Rev Clin Oncol. 2009 Sep;6(9):528-34. doi: 10.1038/nrclinonc.2009.106. Epub 2009 Jul 14. Nat Rev Clin Oncol. 2009. PMID: 19597509 Review.

8

Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors.

Hartl DM, Ferté C, Loriot Y, Gomez Roca C, Bahleda R, Moldovan C, Mir O, Soria JC. Hartl DM, et al. Among authors: loriot y. Invest New Drugs. 2010 Dec;28(6):884-6. doi: 10.1007/s10637-009-9314-9. Epub 2009 Sep 16. Invest New Drugs. 2010. PMID: 19756374 No abstract available.

9

Pemetrexed-induced pneumonitis: a case report.

Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M, Cadranel J, Soria JC. Loriot Y, et al. Clin Lung Cancer. 2009 Sep;10(5):364-6. doi: 10.3816/CLC.2009.n.050. Clin Lung Cancer. 2009. PMID: 19808196

10

Differential expression of biomarkers in men and women.

Planchard D, Loriot Y, Goubar A, Commo F, Soria JC. Planchard D, et al. Among authors: loriot y. Semin Oncol. 2009 Dec;36(6):553-65. doi: 10.1053/j.seminoncol.2009.09.004. Semin Oncol. 2009. PMID: 19995647 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

283 results

Search Page